Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RASHID ATIQUE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1386077378
CMS profile
2791166
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,884.08

93 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,875.18 92
Education $8.90 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RASHID ATIQUE

NPI 1386077378 · CMS profile ID 2791166

Allopathic & Osteopathic Physicians / Internal Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386077378?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RASHID ATIQUE, NPI 1386077378, CMS profile ID 2791166. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386077378?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RASHID ATIQUE, NPI 1386077378, CMS profile ID 2791166. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386077378?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RASHID ATIQUE, NPI 1386077378, CMS profile ID 2791166, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386077378?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

93 matching records · $1,884.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 93 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–93 of 93.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $8.9005/30/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096954416 CMS
Novo Nordisk Inc $6.3405/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097618768 CMS
Medtronic, Inc. $16.0905/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119293939 CMS
Novo Nordisk Inc $15.3305/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096609764 CMS
AstraZeneca Pharmaceuticals LP $21.9905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105479855 CMS
Dexcom, Inc. $23.3205/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153329767 CMS
AstraZeneca Pharmaceuticals LP $15.1005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104237923 CMS
Janssen Pharmaceuticals, Inc $25.0005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078214871 CMS
Novo Nordisk Inc $8.4405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097464716 CMS
Exact Sciences Corporation $14.7705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114580687 CMS
Otsuka America Pharmaceutical, Inc. $14.3505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118856105 CMS
Lilly USA, LLC $20.5805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135355008 CMS
Abbott Laboratories $14.9205/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125037800 CMS
PFIZER INC. $13.8605/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131518421 CMS
Philips North America LLC $15.3405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146902232 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.3704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086234641 CMS
Neurocrine Biosciences, Inc. $18.2004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150864837 CMS
Lilly USA, LLC $20.8604/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135360070 CMS
AstraZeneca Pharmaceuticals LP $16.9504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104209793 CMS
Lilly USA, LLC $24.3904/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135329558 CMS
Abbott Laboratories $16.8104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125037798 CMS
SI-BONE, INC. $18.7404/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120069417 CMS
Otsuka America Pharmaceutical, Inc. $10.4203/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118856103 CMS
Novo Nordisk Inc $21.4803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096596862 CMS
Novo Nordisk Inc $15.1103/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097543803 CMS
Lilly USA, LLC $13.3603/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135329550 CMS
Novo Nordisk Inc $17.7603/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097043215 CMS
AstraZeneca Pharmaceuticals LP $125.0003/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105254746 CMS
Otsuka America Pharmaceutical, Inc. $18.6603/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118856101 CMS
Novartis Pharmaceuticals Corporation $18.5202/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086751117 CMS
ABBVIE INC. $19.1402/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103249809 CMS
Otsuka America Pharmaceutical, Inc. $21.2802/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118856099 CMS
Lilly USA, LLC $18.1102/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135355006 CMS
Abbott Laboratories $23.5202/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125037796 CMS
Otsuka America Pharmaceutical, Inc. $13.3802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118856097 CMS
AstraZeneca Pharmaceuticals LP $45.1202/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104470034 CMS
Lilly USA, LLC $20.3001/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135329554 CMS
Lilly USA, LLC $1.6101/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135352333 CMS
Novo Nordisk Inc $20.4101/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097160398 CMS
Abbott Laboratories $19.9201/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125037794 CMS
Otsuka America Pharmaceutical, Inc. $16.2601/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118856095 CMS
ALK-Abello, Inc $29.5101/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1099888749 CMS
AstraZeneca Pharmaceuticals LP $16.0901/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105848351 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $157.02 3
PY2020 $238.29 9
PY2021 $617.27 32
PY2022 $1,086.21 62
PY2023 $1,292.37 57
PY2024 $1,884.08 93
PY2025 $1,737.78 82

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $283,142.42 102

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seqirus USA Inc $638.55 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295774
Principal investigator 1 Seqirus USA Inc $638.55 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295776
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295778
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295780
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295782
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295784
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295786
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295788
Principal investigator 1 Seqirus USA Inc $321.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295790
Principal investigator 1 Seqirus USA Inc $638.55 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295792
Principal investigator 1 Seqirus USA Inc $888.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295794
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295796
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295798
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295800
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295802
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295804
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295806
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295808
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295810
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295812
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295814
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295817
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295820
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295822
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295824
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295826
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295828
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295831
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295834
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295836
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295838
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295840
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295842
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295844
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295846
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295848
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295850
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295852
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295854
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295856
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295858
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295860
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295862
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295864
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295866
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295868
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295870
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295872
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295874
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295876
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295878
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295880
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295882
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295884
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295886
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295888
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295890
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295892
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295894
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295896
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295898
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295900
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295902
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295904
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295906
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295908
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295910
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295912
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295914
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295916
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295918
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295920
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295922
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295924
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295926
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295928
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295930
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295932
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295934
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295936
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295938
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295940
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295942
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295944
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295946
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295948
Principal investigator 1 Seqirus USA Inc $2,932.88 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295950
Principal investigator 1 Seqirus USA Inc $888.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295952
Principal investigator 1 Seqirus USA Inc $888.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295954
Principal investigator 1 Seqirus USA Inc $888.30 12/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185295956
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,445.68 12/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185550833
Principal investigator 1 Seqirus USA Inc $360.34 12/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296484
Principal investigator 1 Seqirus USA Inc $683.84 11/21/2025 Non-covered Recipient Entity
DM Clinical Research - San Antonio
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811185
Principal investigator 1 Seqirus USA Inc $187.92 11/21/2025 Non-covered Recipient Entity
DM Clinical Research - San Antonio
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811191
Principal investigator 1 Seqirus USA Inc $5,128.80 10/31/2025 Non-covered Recipient Entity
DM Clinical Research - San Antonio
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811177
Principal investigator 1 Seqirus USA Inc $1,409.40 10/31/2025 Non-covered Recipient Entity
DM Clinical Research - San Antonio
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811181
Principal investigator 1 Seqirus USA Inc $2,500.00 10/22/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296500
Principal investigator 1 Seqirus USA Inc $9,500.00 10/22/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296508
Principal investigator 1 Seqirus USA Inc $111.30 09/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296472
Principal investigator 1 Seqirus USA Inc $177.19 09/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296480
Principal investigator 1 Seqirus USA Inc $837.62 09/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296488
Principal investigator 1 Seqirus USA Inc $1,183.50 09/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185296494